HOME >> MEDICINE >> NEWS
Novel antibiotic shows promise in shortening treatment duration of tuberculosis

December 9, 2004 - Scientists at Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) have identified a novel anti-tuberculosis (TB) compound that works better and faster than the current standard of care in mouse models of TB infection. Also, preliminary studies in healthy human volunteers show that the drug is safe. The findings are published in the December 9 issue of Science Express, the online version of the journal Science, and will be published in the January 14 print edition. The studies are reported by scientists at J&JPRD and colleagues at the Swedish Institute for Infectious Disease Control in Solna, Sweden, and Piti-Salptrire School of Medicine in Paris, France.

The compound, called R207910, belongs to a new family of anti-TB agents called diarylquinolines (DARQ) and appears to have better, and more differentiated antibiotic properties than currently used drugs for TB, individually and in combination. R207910 was better at clearing infection from the lungs of mice than the triple cocktail regimen currently recommended by the World Health Organization (WHO). Also, cocktail regimens containing R207910 cleared infection in mice in half the time than the currently used regimen.

"The drug acts through a novel mechanism of action, and is therefore active against all multi-drug resistant (MDR) strains of TB tested so far," says Dr. Koen Andries, D.V.M., Ph.D., Distinguished Research Fellow, Antimicrobial Research at J&JPRD. "A combination including R207910 but excluding rifampin, one of the current TB drugs, looks especially promising. A combination excluding rifampin would be compatible with anti-HIV drugs, making it suitable for treating patients co-infected with HIV and TB."

The World Health Organization (WHO) has declared TB a global health crisis. TB now infects one-third of the world's population and causes close to nine million new cases of active TB and 2 million deaths each year. Unfortunately, many TB strains h
'"/>


9-Dec-2004


Page: 1 2 3 4

Related medicine news :

1. Novel therapy tested in mice could chase away cat allergies
2. Novel p53 gene-based therapy boosts immune system and reduces tumor size
3. Novel drugs help solve Gleevec resistance
4. Novel imaging technique shows abnormal brain anatomy in children with ADHD
5. Novel drug-antidote strategy provides greater control of drug action
6. Novel imaging technique shows lymph nodes, metastases in breast cancer without surgery
7. Novel delivery method for nutrients wins Kaye Innovation Award for Hebrew university students
8. Novel vitamin discovery offers clues for cancer chemotherapy and lipid disorders
9. Novel findings about neovessel formation
10. Novel MRI technique provides clear images of blood flow
11. Novelty-seeking teens may be more easily influenced by tobacco advertisements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/8/2019)... PARK, Md. (PRWEB) , ... October 08, 2019 ... ... observe fungal infection progression in live samples, Meiqing Shi, associate professor with the ... the field. In his latest paper published in Nature Communications, Shi and his ...
(Date:10/8/2019)... ... ... Over the past three decades, Buffalo Wings & Rings has elevated the ... providing a higher-quality product and experience than the competition. Now, the club-level sports restaurant ... MUG FOR THE CAUSE" campaign in support of Breast Cancer Awareness Month. , ...
(Date:10/8/2019)... , ... October 08, 2019 , ... METAvivor Research and ... cancer, announced the launch of its Stage IV Stampede campaign. The campaign will commence ... Washington, DC that will include an advocacy boot camp, a march, a Die-In (hosted ...
(Date:10/8/2019)... ... October 08, 2019 , ... The University of California San ... Awards 1st Round (Top Ten) Finalist in its Best Cardiovascular Digital Diagnostic category. ... promote faster, better, more cost-effective healthcare by improving outcomes such as shorter hospital ...
(Date:10/8/2019)... ... October 08, 2019 , ... Dr. Marc Lazare, ... attended an advanced Level III training in Cagliari, Italy, this past September to ... place September 16-19, 2019 at the Sardinia Dental Teaching Center and covered several ...
Breaking Medicine News(10 mins):
(Date:10/8/2019)... ... October 09, 2019 , ... “When Seconds Count: Reports From an Emergency Medical ... the HEMS world through telling the real stories of the EMS flight crew. “When ... author Jay A. Humphrey, an EMS helicopter pilot. He has been a pilot in ...
(Date:10/8/2019)... (PRWEB) , ... October 08, 2019 , ... ... participated in an advanced dental implant seminar to enhance his skill and knowledge ... country, The Implant Dentistry Continuum™ is a four-part series of classes that combines ...
(Date:10/8/2019)... , ... October 08, 2019 , ... A free, interactive ... this month in Austin, Texas. The event, featuring thought leaders, innovators and health experts, ... , Held from 2:00 p.m. to 5:30 p.m. CT on October 19 at ...
Breaking Medicine Technology:
Cached News: